CD4+ follicular helper T cell infiltration predicts breast cancer survival

Journal of Clinical Investigation

Volumn 123, Issue 7, 2013, Pages 2873-2892

  Gu Trantien, Chunyan ^a   Loi, Sherene ^a,c   Garaud, Soizic ^a   Equeter, Carole ^a   Libin, Myriam ^a   De Wind, Alexandre ^a   Ravoet, Marie ^a,d   Le Buanec, Hélène ^a   Sibille, Catherine ^a   Manfouo Foutsop, Germain ^a   Veys, Isabelle ^a   Haibe Kains, Benjamin ^a,b,e   Singhal, Sandeep K ^a   Michiels, Stefan ^a,f   Rothé, Françoise ^a   Salgado, Roberto ^a   Duvillier, Hugues ^a   Ignatiadis, Michail ^a   Desmedt, Christine ^a   Bron, Dominique ^a   Larsimont, Denis ^a   Piccart, Martine ^a   Sotiriou, Christos ^a   Willard Gallo, Karen ^a   more..

^a JULES BORDET INSTITUTE   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^e CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^f INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL13 CHEMOKINE;

ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CELL INFILTRATION; CYTOKINE PRODUCTION; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE ACTIVATION; LYMPHOCYTIC INFILTRATION; MEMORY CELL; PREDICTIVE VALUE; PRIMARY TUMOR; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; TH2 CELL; TUMOR IMMUNITY;

ANTIGENS, CD; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY; TRANSCRIPTOME;

EID: 84879661529     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI67428     Document Type: Article

References (89)

1. Perou CM, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752.
2. Sorlie T, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98(19):10869-10874. (Pubitemid 32878711)
3. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009;360(8):790-800.
4. Sotiriou C, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006;98(4):262-272. (Pubitemid 43264710)
5. Ascierto ML, et al. An immunologic portrait of cancer. J Transl Med. 2011;9:146.
6. Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol. 2007;8(8):R157.
7. Alexe G, et al. High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res. 2007;67(22):10669-10676. (Pubitemid 350145892)
8. Desmedt C, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res . 2008; 14(16):5158-5165.
9. Schmidt M, et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 2008;68(13):5405-5413.
10. Rody A, et al. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res . 2009;11(2):R15.
11. Yau C, Esserman L, Moore DH, Waldman F, Sninsky J, Benz CC. A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Res. 2010;12(5):R85.
12. Ascierto ML, et al. A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat. 2012; 131(3):871-880.
13. Rody A, et al. A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res. 2011;13(5):R97.
14. Rahir G, Moser M. Tumor microenvironment and lymphocyte infiltration. Cancer Immunol Immunother. 2012;61(6):751-759.
15. Mahmoud SM, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29(15):1949-1955.
16. Mahmoud S, Lee A, Ellis I, Green A. CD8(+) T lymphocytes infiltrating breast cancer: A promising new prognostic marker? Oncoimmunology . 2012; 1(3):364-365.
17. Bos R, Marquardt KL, Cheung J, Sherman LA. Functional differences between low- and high-affinity CD8(+) T cells in the tumor environment. Oncoimmunology. 2012;1(8):1239-1247.
18. Bos R, Sherman LA. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res. 2010; 70(21):8368-8377.
19. Ruffell B, DeNardo DG, Affara NI, Coussens LM. Lymphocytes in cancer development: polarization towards pro-tumor immunity. Cytokine Growth Factor Rev. 2010;21(1):3-10.
20. Zamarron BF, Chen W. Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci. 2011;7(5):651-658.
21. Gobert M, et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 2009;69(5):2000-2009.
22. Wilke CM, et al. Th17 cells in cancer: help or hindrance? Carcinogenesis. 2011;32(5):643-649.
23. Ye J, Livergood RS, Peng G. The role and regulation of human Th17 cells in tumor immunity. Am J Pathol. 2013;182(1):10-20.
24. deLeeuw RJ, Kost SE, Kakal JA, Nelson BH. The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res. 2012;18(11):3022-3029.
25. de Chaisemartin L, et al. Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. Cancer Res. 2011;71(20):6391-6399.
26. Dieu-Nosjean MC, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. 2008; 26(27):4410-4417.
27. Coppola D, et al. Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. Am J Pathol. 2011;179(1):37-45.
28. Vinuesa CG, Cyster JG. How T cells earn the follicular rite of passage. Immunity. 2011;35(5):671-680.
29. Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM. Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A. 2012; 109(8):2796-2801.
30. Chtanova T, et al. Identification of T cell-restricted genes, and signatures for different T cell responses, using a comprehensive collection of microarray datasets. J Immunol. 2005;175(12):7837-7847. (Pubitemid 41798344)
31. Miyara M, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity . 2009;30(6):899-911.
32. Lee MS, Hanspers K, Barker CS, Korn AP, McCune JM. Gene expression profiles during human CD4+ T cell differentiation. Int Immunol. 2004; 16(8):1109-1124. (Pubitemid 39136728)
33. Ravoet M, et al. Molecular profiling of CD3-CD4+ T cells from patients with the lymphocytic variant of hypereosinophilic syndrome reveals targeting of growth control pathways. Blood . 2009; 114(14):2969-2983.
34. Zaunders JJ, et al. Early proliferation of CCR5(+) CD38(+++) antigen-specific CD4(+) Th1 effector cells during primary HIV-1 infection. Blood. 2005; 106(5):1660-1667. (Pubitemid 41208579)
35. Baniyash M. TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response. Nat Rev Immunol. 2004;4(9):675-687. (Pubitemid 39223074)
36. Fazilleau N, Mark L, McHeyzer-Williams LJ, McHeyzer-Williams MG. Follicular helper T cells: lineage and location. Immunity. 2009;30(3):324-335.
37. Balkwill FR. The chemokine system and cancer. J Pathol. 2012;226(2):148-157.
38. Razis E, et al. Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression. Clin Breast Cancer. 2012;12(3):183-193.
39. Panse J, et al. Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients. Br J Cancer . 2008;99(6):930-938.
40. Link A, et al. Association of T-zone reticular networks and conduits with ectopic lymphoid tissues in mice and humans. Am J Pathol . 2011; 178(4):1662-1675.
41. Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol. 2011;29:621-663.
42. Viegas MS, et al. CD38 plays a role in effective containment of mycobacteria within granulomata and polarization of Th1 immune responses against Mycobacterium avium. Microbes Infect . 2007; 9(7):847-854. (Pubitemid 46901041)
43. Crotty S. The 1-1-1 fallacy. Immunol Rev . 2012; 247(1):133-142.
44. Ignatiadis M, et al. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J Clin Oncol . 2012; 30(16):1996-2004.
45. Grange C, et al. Phenotypic characterization and functional analysis of human tumor immune infiltration after mechanical and enzymatic disaggregation. J Immunol Methods. 2011;372(1-2):119-126.
46. Hayden MS, Ghosh S. NF-kappaB, the first quar-ter- century: remarkable progress and outstanding questions. Genes Dev. 2012;26(3):203-234.
47. Kim TW, et al. Pellino 2 is critical for Toll-like receptor/interleukin-1 receptor (TLR/IL-1R)-mediated post-transcriptional control. J Biol Chem. 2012; 287(30):25686-25695.
48. Chang M, et al. The ubiquitin ligase Peli1 negatively regulates T cell activation and prevents autoimmunity. Nat Immunol. 2011;12(10):1002-1009.
49. Yu KY, Kwon HJ, Norman DA, Vig E, Goebl MG, Harrington MA. Cutting edge: mouse pellino-2 modulates IL-1 and lipopolysaccharide signaling. J Immunol. 2002;169(8):4075-4078. (Pubitemid 35178172)
50. Macian F, Lopez-Rodriguez C, Rao A. Partners in transcription: NFAT and AP-1. Oncogene. 2001; 20(19):2476-2489. (Pubitemid 32531304)
51. Xiao G, Deng A, Liu H, Ge G, Liu X. Activator protein 1 suppresses antitumor T-cell function via the induction of programmed death 1. Proc Natl Acad Sci U S A. 2012;109(38):15419-15424.
52. Ghebeh H, et al. Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells. Int J Cancer. 2007;121(4):751-758. (Pubitemid 47106203)
53. Good-Jacobson KL, Szumilas CG, Chen L, Sharpe AH, Tomayko MM, Shlomchik MJ. PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells. Nat Immunol. 2010;11(6):535-542.
54. Mihalj M, Kellermayer Z, Balogh P. Follicles in gut-associated lymphoid tissues create preferential survival niches for follicular Th cells escaping Thy-1-specific depletion in mice [published online ahead of print February 28, 2013]. Int Immunol. doi:10.1093/intimm/dxt001.
55. Inozume T, et al. Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells. J Immunother . 2010; 33(9):956-964.
56. O'Shea JJ, Paul WE. Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science. 2010;327(5969):1098-1102.
57. Galon J, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960-1964. (Pubitemid 44498003)
58. Yoon HH, Orrock JM, Foster NR, Sargent DJ, Smyrk TC, Sinicrope FA. Prognostic impact of FoxP3+ regulatory T cells in relation to CD8+ T lymphocyte density in human colon carcinomas. PloS One. 2012;7(8):e42274.
59. Shankaran V, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature . 2001; 410(6832):1107-1111. (Pubitemid 32391043)
60. Curtis NJ, Primrose JN, Thomas GJ, Mirnezami AH, Ottensmeier CH. The adaptive immune response to colorectal cancer: from the laboratory to clinical practice. Eur J Surg Oncol. 2012;38(10):889-896.
61. Haabeth OA, et al. Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun. 2011;2:240.
62. Braumuller H, et al. T-helper-1-cell cytokines drive cancer into senescence. Nature . 2013; 494(7437):361-365.
63. Ji Y, Zhang W. Th17 cells: positive or negative role in tumor? Cancer Immunol Immunother. 2010; 59(7):979-987.
64. Kryczek I, et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood. 2009; 114(6):1141-1149.
65. Curiel TJ, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004; 10(9):942-949. (Pubitemid 39273735)
66. Ladoire S, et al. Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat. 2011; 125(1):65-72.
67. Kim M, et al. Expression of foxp3 in colorectal cancer but not in treg cells correlates with disease progression in patients with colorectal cancer. PloS One. 2013;8(1):e53630.
68. Watanabe MA, Oda JM, Amarante MK, Cesar Voltarelli J. Regulatory T cells and breast cancer: implications for immunopathogenesis. Cancer Metastasis Rev. 2010;29(4):569-579.
69. Bates GJ, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 2006;24(34):5373-5380. (Pubitemid 46623168)
70. West NR, et al. Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer. Br J Cancer. 2013; 108(1):155-162.
71. Breitfeld D, et al. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J Exp Med. 2000;192(11):1545-1552.
72. Schaerli P, Willimann K, Lang AB, Lipp M, Loetscher P, Moser B. CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J Exp Med . 2000; 192(11):1553-1562.
73. McHeyzer-Williams M, Okitsu S, Wang N, McHeyzer-Williams L. Molecular programming of B cell memory. Nat Rev Immunol. 2012;12(1):24-34.
74. Ramiscal RR, Vinuesa CG. T-cell subsets in the germinal center. Immunol Rev. 2013;252(1):146-155.
75. Nelson BH. CD20+ B cells: the other tumor-infiltrating lymphocytes. J Immunol. 2010;185(9):4977-4982.
76. Lohr M, et al. The prognostic relevance of tumour-infiltrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancer. Cancer Lett. 2013;333(2):222-228.
77. Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO, Green AR. The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat. 2012;132(2):545-553.
78. Nielsen JS, et al. CD20+ tumor-infiltrating lympho- cytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res. 2012; 18(12):3281-3292.
79. Ladanyi A, et al. Prognostic impact of B-cell density in cutaneous melanoma. Cancer Immunol Immunother. 2011;60(12):1729-1738.
80. Maletzki C, Jahnke A, Ostwald C, Klar E, Prall F, Linnebacher M. Ex-vivo clonally expanded B lymphocytes infiltrating colorectal carcinoma are of mature immunophenotype and produce functional IgG. PLoS One. 2012;7(2):e32639.
81. Coronella JA, et al. Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast. J Immunol. 2002; 169(4):1829-1836. (Pubitemid 34857644)
82. Coronella-Wood JA, Hersh EM. Naturally occurring B-cell responses to breast cancer. Cancer Immunol Immunother. 2003;52(12):715-738. (Pubitemid 37491701)
83. Bianchini G, et al. Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. J Clin Oncol. 2010;28(28):4316-4323.
84. Foo SY, Phipps S. Regulation of inducible BALT formation and contribution to immunity and pathology. Mucosal Immunol. 2010;3(6):537-544.
85. Martinet L, et al. Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Res. 2011;71(17):5678-5687.
86. Muller G, Hopken UE, Lipp M. The impact of CCR7 and CXCR5 on lymphoid organ development and systemic immunity. Immunol Rev . 2003; 195:117-135. (Pubitemid 37153458)
87. Wang C, Hillsamer P, Kim CH. Phenotype, effector function, and tissue localization of PD-1-expressing human follicular helper T cell subsets. BMC Immunol. 2011;12:53.
88. Denkert C, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(1):105-113.
89. Haibe-Kains B, et al. A three-gene model to robustly identify breast cancer molecular subtypes. J Natl Cancer Inst. 2012;104(4):311-325.